Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.

Nuo Therapeutics’ flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.

Type
Public
HQ
Gaithersburg, US
Size (employees)
46 (est)
Website
nuot.com
Nuo Therapeutics is headquartered in Gaithersburg, US
Report incorrect company information

Nuo Therapeutics Office Locations

Nuo Therapeutics has an office in Gaithersburg
Gaithersburg, US (HQ)
1 207A Perry Pkwy
Show all (1)
Report incorrect company information

Nuo Therapeutics Financials and Metrics

Nuo Therapeutics Revenue

Nuo Therapeutics's revenue was reported to be $472.45 k in FY, 2016 which is a 95.9% decrease from the previous period.
USD

Revenue (Q2, 2018)

298.3 k

Net income (Q2, 2018)

(1.3 m)

EBIT (Q2, 2018)

(1.3 m)

Cash (30-Jun-2018)

373.3 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.6 m7.8 m11.5 m472.4 k

Revenue growth, %

(33%)48%(96%)

Cost of goods sold

8.4 m6.6 m

Gross profit

3.2 m1.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Revenue

2.3 m1.7 m4.8 m2.9 m2.2 m1.4 m134.9 k176.8 k172.7 k162.2 k298.3 k

Cost of goods sold

1.9 m1.3 m

Gross profit

473.1 k401.6 k

Gross profit Margin, %

20%24%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.3 m15.9 m922.3 k2.6 m

Inventories

1.3 m2.3 m804.5 k70 k

Current Assets

10 m21.9 m3 m3.4 m

PP&E

919.5 k925.2 k1.1 m486.1 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Cash

25 m20 m11.8 m6.9 m4.1 m685.5 k6.1 m3.9 m1.3 m1.9 m373.3 k

Inventories

591.6 k544.7 k1 m717.1 k603.8 k158.6 k78.1 k48.2 k64.7 k367.5 k37.5 k

Current Assets

30.6 m25.7 m18.6 m12.8 m12.3 m3.1 m8.1 m5.6 m2.1 m2.6 m652.1 k

PP&E

706.4 k757.2 k999.1 k874.1 k865.1 k983.7 k787.3 k691.1 k388.4 k155.9 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(20.2 m)(18.9 m)(52.8 m)(5.7 m)

Depreciation and Amortization

1.1 m613.5 k741 k836.2 k

Inventories

(210.2 k)(1.1 m)272 k(21.6 k)

Accounts Payable

5.2 m(1.5 m)(811 k)(2.5 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Net Income

(4.8 m)4.1 m(870.2 k)(13.8 m)(4.9 m)(1.3 m)(1.9 m)(1.7 m)(1.4 m)(1.3 m)

Depreciation and Amortization

51.8 k

Inventories

591.6 k544.7 k367.5 k(2.8 k)

Accounts Payable

8.4 m1.7 m2 m1.7 m2.5 m728.9 k1.3 m498.3 k378.3 k434.5 k143.2 k
USDY, 2018

Financial Leverage

-3 x
Show all financial metrics
Report incorrect company information

Nuo Therapeutics Company Life and Culture

Report incorrect company information